Get the Stockscreener App
6.32
8.55%
-0.58
Atara Biotherapeutics Inc stock is traded at $6.32, with a volume of 147.80K.
It is down -8.55% in the last 24 hours and up +41.80% over the past month.
Atara Biotherapeutics Inc operates in the United States healthcare sector. It focuses on developing transformative therapies for patients with serious diseases, including solid tumors, hematologic cancers, and autoimmune diseases. It operates and manages business as one operating and reportable segment which is the business of developing therapeutics. The company's product candidates comprise Tab-cel, ATA188, and ATA3219 (CAR T Platform).
See More
Previous Close:
$6.90
Open:
$6.8
24h Volume:
147.80K
Relative Volume:
0.40
Market Cap:
$45.28M
Revenue:
$151.93M
Net Income/Loss:
$23.40M
P/E Ratio:
2.8829
EPS:
2.1922
Net Cash Flow:
$-69.80M
1W Performance:
+22.05%
1M Performance:
+41.80%
6M Performance:
-47.94%
1Y Performance:
-8.02%
1-Day Range:
$6.21
$7.00
1-Week Range:
$5.50
$7.2999
52-Week Range:
$3.92
$19.14
Atara Biotherapeutics Inc Stock (ATRA) Company Profile
Name
Atara Biotherapeutics Inc
Sector
Industry
Phone
805-623-4211
Address
1280 RANCHO CONEJO BLVD, THOUSAND OAKS, CA
Compare ATRA vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ATRA
Atara Biotherapeutics Inc
|
6.28 | 49.75M | 151.93M | 23.40M | -69.80M | 2.1922 |
|
VRTX
Vertex Pharmaceuticals Inc
|
474.39 | 121.46B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
747.11 | 78.93B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
703.05 | 43.87B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
314.94 | 42.07B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
284.10 | 31.65B | 5.36B | 287.73M | 924.18M | 2.5229 |
Atara Biotherapeutics Inc Stock (ATRA) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-13-26 | Downgrade | Canaccord Genuity | Buy → Hold |
| Nov-09-23 | Downgrade | Evercore ISI | Outperform → In-line |
| Nov-09-23 | Downgrade | H.C. Wainwright | Buy → Neutral |
| Nov-09-23 | Downgrade | Mizuho | Buy → Neutral |
| Jul-20-22 | Downgrade | Citigroup | Neutral → Sell |
| Jul-13-22 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-13-22 | Downgrade | Stifel | Buy → Hold |
| May-10-22 | Downgrade | Citigroup | Buy → Neutral |
| May-13-21 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-09-20 | Downgrade | Citigroup | Buy → Neutral |
| Dec-08-20 | Reiterated | H.C. Wainwright | Buy |
| Nov-10-20 | Reiterated | H.C. Wainwright | Buy |
| Jun-30-20 | Initiated | Evercore ISI | Outperform |
| Jun-15-20 | Initiated | H.C. Wainwright | Buy |
| Apr-23-20 | Upgrade | Citigroup | Neutral → Buy |
| Nov-08-19 | Downgrade | JP Morgan | Overweight → Neutral |
| Sep-27-19 | Downgrade | Goldman | Neutral → Sell |
| Sep-16-19 | Downgrade | Jefferies | Buy → Hold |
| Jun-04-19 | Upgrade | Citigroup | Sell → Neutral |
| May-30-19 | Initiated | ROTH Capital | Buy |
| May-23-19 | Initiated | Stifel | Buy |
| Jan-23-19 | Initiated | Mizuho | Buy |
| Apr-10-18 | Initiated | JP Morgan | Overweight |
| Mar-16-18 | Initiated | Guggenheim | Neutral |
| Mar-05-18 | Reiterated | Jefferies | Buy |
| Feb-28-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Feb-15-18 | Downgrade | Citigroup | Neutral → Sell |
| Jan-03-18 | Upgrade | Citigroup | Sell → Neutral |
| Oct-06-17 | Resumed | Goldman | Neutral |
View All
Atara Biotherapeutics Inc Stock (ATRA) Latest News
Weekly Trades: Will Atara Biotherapeutics Inc benefit from AI trendsQuarterly Market Review & Stock Portfolio Risk Management - baoquankhu1.vn
Atara schedules FDA meeting on tabelecleucel license application - Investing.com South Africa
Atara Biotherapeutics Inc Provides Regulatory Update on Tabelecleucel - marketscreener.com
Precision Trading with Atara Biotherapeutics Inc. (ATRA) Risk Zones - Stock Traders Daily
Atara (ATRA) Schedules FDA Meeting to Address CRL for Tabelecleu - GuruFocus
Atara Plans FDA Type A Meeting on EBVALLO - TipRanks
Atara schedules FDA meeting on tabelecleucel license application By Investing.com - Investing.com Canada
Atara Biotherapeutics schedules FDA Type A meeting on EBVALLO BLA complete response - TradingView
Atara Biotherapeutics Provides Regulatory Update on Tabelecleucel - Business Wire
Atara Biotherapeutics Stock Jumps 18% as FDA Shake-Up Puts Ebvallo Back in Focus - TechStock²
12 Health Care Stocks Moving In Monday's Pre-Market Session - Benzinga
Why Lisata Therapeutics Shares Are Trading Higher By Over 20%; Here Are 20 Stocks Moving Premarket - Benzinga
Aug Closing: Can Atara Biotherapeutics Inc sustain earnings growth2026 Fundamental Recap & Risk Controlled Daily Plans - baoquankhu1.vn
Aug Chart Watch: Is Atara Biotherapeutics Inc being accumulated by smart moneyJobs Report & Weekly Breakout Stock Alerts - baoquankhu1.vn
Why Atara Biotherapeutics Inc. stock is popular among millennials2025 Trading Recap & Verified Entry Point Signals - Naître et grandir
Aug Momentum: Is Atara Biotherapeutics Inc forming a breakout patternJuly 2025 Catalysts & Short-Term Swing Trade Alerts - baoquankhu1.vn
Profit Review: Will Atara Biotherapeutics Inc benefit from green energy policiesEarnings Recap Report & Precise Swing Trade Entry Alerts - baoquankhu1.vn
ATRA Rises On Pushing For Meeting With FDA On Rare Disease Drug Rejection - Stocktwits
Atara Biotherapeutics provides regulatory update on tabelecleucel - marketscreener.com
Atara, Pierre Fabre seek FDA meeting on EBVALLO - TipRanks
Atara Biotherapeutics (ATRA) and Partner Seek FDA Meeting for Ta - GuruFocus
Atara Biotherapeutics partner seeks Type A FDA meeting on tabelecleucel following CRL - TradingView
Atara Biotherapeutics (ATRA) requests FDA Type A meeting on EBVALLO™ - Stock Titan
Atara Biotherapeutics Inc expected to post a loss of 37 cents a shareEarnings Preview - TradingView
Insider sale: ATRA (NASDAQ: ATRA) 7,788 RSU shares settled 03/01/2026 - Stock Titan
ATRA (NASDAQ) insider resale notice: 4,759 RSU shares reported - Stock Titan
Technical Reactions to ATRA Trends in Macro Strategies - Stock Traders Daily
ATRA Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
ATRA Should I Buy - Intellectia AI
Atara Biotherapeutics (ATRA) Shares Rise Despite FDA Rejection - GuruFocus
Atara jumps amid report on FDA’s U-turn on cell therapy - Seeking Alpha
Market Overview: Can Atara Biotherapeutics Inc stock double in the next yearStock Surge & Free Fast Entry Momentum Trade Alerts - baoquankhu1.vn
Atara Biotherapeutics Provides a Business Update - BioSpace
Atara Biotherapeutics (ATRA) Adjusts Key Financial Agreement - GuruFocus
Atara Biotherapeutics Extends Royalty Milestone, Issues Warrant - TipRanks
Atara Biotherapeutics Defers $9 Million Milestone Payment to 2028, Issues 400,000-Share Warrant to HCR - TradingView
Atara extends $9M milestone payment deadline to 2028 - Investing.com
Atara (NASDAQ: ATRA) extends $9M HCRx payment and grants 400,000-share warrant - Stock Titan
Insider Buy: Is GLBLW showing insider buyingIndex Update & Verified Chart Pattern Signals - baoquankhu1.vn
What is the Moat Score of Atara Biotherapeutics Inc.2025 Sector Review & Technical Pattern Based Buy Signals - mfd.ru
There's No Escaping Atara Biotherapeutics, Inc.'s (NASDAQ:ATRA) Muted Revenues - simplywall.st
Exit Recap: Can Atara Biotherapeutics Inc. weather a recessionQuarterly Performance Summary & Weekly Top Stock Performers List - mfd.ru
What are analysts’ price targets for Atara Biotherapeutics Inc.July 2025 WrapUp & Free Expert Approved Momentum Trade Ideas - mfd.ru
Take Profit: Will International Tower Hill Mines Ltd outperform the market in YEARJuly 2025 Short Interest & High Yield Stock Recommendations - baoquankhu1.vn
Is Atara Biotherapeutics Inc. impacted by rising ratesJuly 2025 Highlights & Detailed Earnings Play Alerts - mfd.ru
MSN Money - MSN
Will Atara Biotherapeutics Inc. stock recover faster than peersJuly 2025 Price Swings & AI Forecasted Entry/Exit Points - mfd.ru
Is Atara Biotherapeutics Inc. stock ready for breakout2025 Trading Recap & Long-Term Capital Growth Strategies - mfd.ru
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Atara Biotherapeutics, Inc.ATRA - PR Newswire
Can Atara Biotherapeutics Inc. stock double in the next yearTrend Reversal & Community Consensus Trade Alerts - mfd.ru
How Atara Biotherapeutics Inc. stock trades during market volatility2025 Key Lessons & Stepwise Trade Signal Guides - mfd.ru
Atara Biotherapeutics Inc Stock (ATRA) Financials Data
Revenue
Net Income
Cash Flow
EPS
Atara Biotherapeutics Inc Stock (ATRA) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Nguyen AnhCo | President and CEO |
Mar 02 '26 |
Sale |
5.09 |
2,996 |
15,237 |
61,978 |
0.41%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):